[Hallucinogen caused motility disorders in rats as potential psychosis relevant animal model].
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001921:Brain / Q000187:drug effects; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006213:Hallucinogens / Q000494:pharmacology*; D006801:Humans; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D008784:Methysergide / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects*; D011605:Psychoses, Substance-Induced / Q000523:psychology*; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects; D011985:Receptors, Serotonin / Q000187:drug effects; D012701:Serotonin / Q000378:metabolism
D006213:Hallucinogens; D011954:Receptors, Dopamine; D011985:Receptors, Serotonin; D012701:Serotonin; D008238:Lysergic Acid Diethylamide; D001058:Apomorphine; D004298:Dopamine; D008784:Methysergide
Durch Halluzinogene ausgelöste Motilitätsstörungen bei Ratten als potentiell psychoserelevantes Tiermodell.